Transgenomic Showcases How Multiplexed ICE COLD-PCR™ is Advancing Precision Medicine in Address at Next Generation Diagnostics Summit

Talk at “Clinical Application of Cell-Free DNA-Enabling Non-Invasive Diagnostics” Shows How Multiplexed ICE COLD-PCR Allows Accurate, Flexible Cancer Monitoring from Blood Samples

OMAHA, Neb.--()--Transgenomic, Inc. (NASDAQ:TBIO) today announced that Ben Legendre, PhD, Technical Director, Laboratory Operations, Transgenomic, Inc. will deliver a presentation at the 7th Annual Next Generation Diagnostics Summit. In his talk, Dr. Legendre will highlight how Transgenomic’s breakthrough Multiplexed ICE COLD-PCR™ (MX-ICP) technology enables use of liquid biopsies and facilitates broad adoption of precision and personalized medicine.

In his talk, Dr. Legendre notes that the use of “liquid biopsies” is increasingly important for molecular diagnostics and pharmacodynamic monitoring of patients during cancer therapy when limited or no tumor tissue is available. The ability of MX-ICP to efficiently detect genetic alterations down to 0.01% in most sample types and its compatibility with most downstream analysis platforms mean that efficient detection of mutations is feasible and practical for most laboratories. MX-ICP can currently be accessed for research use via Transgenomic’s Biomarker Discovery service and its ICEme™ kits, and for diagnostic use through its CLIA laboratory mutation detection tests. MX-ICP kits for diagnostic use will be launched in Europe later this year.

Dr. Legendre commented, “We welcome the opportunity to discuss the advantages of our MX-ICP technology with our colleagues at this conference, which focuses on the cancer biomarkers and liquid biopsies that are essential for adoption of precision medicine. MX-ICP has the combination of ultra-high sensitivity and platform and workflow flexibility needed to make routine use of liquid biopsies a practical reality. The recent launch of our MX-ICP-based Biomarker Discovery service, our ICEme kits for researchers and our EGFR CLIA tests for diagnostic use in lung and colorectal cancer detection and monitoring are raising the profile of this important new technology and our pipeline of unique MX-ICP products for researchers and physicians.”

In his talk, Dr. Legendre describes how Multiplexed ICE COLD-PCR preferentially amplifies sequence alterations in challenging samples, delivering unbiased enrichment of gene regions that allows determination of all point mutations and insertions/deletions using Sanger or next generation sequencing or droplet digital PCR at very high sensitivities--approximately 0.01%--in samples with limited amounts of DNA, such as plasma or fine needle aspirates. In addition, its multiplexed format allows sensitive detection and monitoring of all genetic alterations in multiple targets using a single DNA sample.

Dr. Legendre will present, “The Use of Multiplexed ICE COLD-PCR Coupled to Multiple Downstream Analysis Platforms for Detection of Low Level Sequence Alterations,” at the Seventh Annual Next Generation Diagnostics Summit--Clinical Application of Cell-Free DNA in Washington, DC, on August 20, 2015 at 9:30 am.

For more information on Transgenomic’s Biomarker Discovery services, click here. For information about its ICEme kits, click here. For information about its EGFR CLIA tests, click here.

About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 15, 2015. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Contacts

Media Contact
BLL Partners LLC
Barbara Lindheim, 212-584-2276
blindheim@bllbiopartners.com
or
Investor Contact
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com

Contacts

Media Contact
BLL Partners LLC
Barbara Lindheim, 212-584-2276
blindheim@bllbiopartners.com
or
Investor Contact
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com